This agreement has to do with the company’s plans for a Phase 3 clinical trial of oral sulopenem etzadroxil-probenecid. This is a drug designed to treat patients that are suffering from uncomplicated urinary tract infections.
The special protocol assessment (SPA) agreement sets up specific parameters for the Phase 3 clinical trial. The goal is to meet the requirements the FDA has listed for the resubmission of Iterum Therapeutics’ New Drug Application (NDA) for the treatment.
Corey Fishman, CEO of Iterum Therapeutics, said the following in a news release.
“The SPA underscores our alignment with the FDA on important regulatory, clinical and scientific requirements for our planned Phase 3 trial in uUTI and reflects our ongoing commitment to bring this valuable therapy to market. We are excited about this important milestone and are looking forward to starting recruitment for this trial as soon as possible.”
News of the FDA agreement has ITRM stock seeing heavy trading on Monday. As of this writing, some 86 million shares of the stock have changed hands. That’s a massive leap over its daily average trading volume of about 1.1 million shares.
ITRM stock is up 72.5% as of Monday morning.
There’s more stock market news to dive into below!
We’ve got all the stock coverage that traders need to get through Monday! That includes what’s hitting Uber (NYSE:UBER), why Mullen Automotive (NASDAQ:MULN) is rising, as well as what’s happening with casino stocks today. You can read all that news at the links below!
More Monday Stock Market News
- UBER Stock Slides on Reports of Political Lobbying, Lawbreaking
- Mullen (MULN) Stock Soars 11% on DelPack Logistics Deal
- Why Are Casino Stocks WYNN, LVS Down Today?
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.